Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

955 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L. Tsujino T, et al. Among authors: azuma h. Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y. Nat Commun. 2023. PMID: 36650183 Free PMC article.
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer.
Ichihashi A, Inamoto T, Uchimoto T, Nakamura KO, Komura K, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Yamamoto K, Kato R, Ijiri Y, Hayashi T, Azuma H. Ichihashi A, et al. Among authors: azuma h. In Vivo. 2023 Jan-Feb;37(1):143-148. doi: 10.21873/invivo.13063. In Vivo. 2023. PMID: 36593015 Free PMC article.
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H. Inamoto T, et al. Among authors: azuma h. Cancer Diagn Progn. 2023 May 3;3(3):370-376. doi: 10.21873/cdp.10226. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168961 Free PMC article.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Komura K, Tokushige S, Ishida M, Hirosuna K, Yamazaki S, Nishimura K, Ajiro M, Ohno T, Nakamori K, Kinoshita S, Tsujino T, Maenosono R, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: azuma h. Cancer Sci. 2023 Dec;114(12):4622-4631. doi: 10.1111/cas.15976. Epub 2023 Sep 26. Cancer Sci. 2023. PMID: 37752769 Free PMC article.
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
Tsujino T, Komura K, Inamoto T, Maenosono R, Hashimoto T, Adachi T, Hirasawa Y, Tokushige S, Ohno T, Yamazaki S, Fukushima T, Nakamura K, Yano Y, Nishimura K, Kinoshita S, Nakamori K, Tsutsumi T, Matsunaga T, Yoshikawa Y, Uchimoto T, Takai T, Minami K, Uehara H, Hirano H, Nomi H, Takahara K, Ohno Y, Azuma H. Tsujino T, et al. Among authors: azuma h. World J Urol. 2023 Dec;41(12):3585-3591. doi: 10.1007/s00345-023-04687-3. Epub 2023 Nov 4. World J Urol. 2023. PMID: 37924336
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, Hayashi T, Ura A, Ohno T, Yamazaki S, Nakamori K, Kinoshita S, Maenosono R, Ajiro M, Yoshikawa Y, Takai T, Tsutsumi T, Taniguchi K, Tanaka T, Takahara K, Konuma T, Inamoto T, Hirose Y, Ono F, Shiraishi Y, Yoshimi A, Azuma H. Komura K, et al. Among authors: azuma h. Mol Cancer. 2023 Nov 18;22(1):185. doi: 10.1186/s12943-023-01897-6. Mol Cancer. 2023. PMID: 37980528 Free PMC article.
Pattern of expression of microRNA in patients with radiation induced bladder injury.
Nakamura K, Ohno T, Inamoto T, Takai T, Uchimoto T, Fukushima T, Nishimura K, Yano Y, Nishio K, Kinoshita S, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Komura K, Takahara K, Azuma H. Nakamura K, et al. Among authors: azuma h. Oncology. 2023 Dec 29. doi: 10.1159/000535993. Online ahead of print. Oncology. 2023. PMID: 38160665
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Tsujino T, et al. Among authors: azuma h. Cancer Med. 2023 Oct;12(19):19414-19422. doi: 10.1002/cam4.6536. Epub 2023 Sep 14. Cancer Med. 2023. PMID: 37706578 Free PMC article.
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Nukaya T, Takahara K, Yoshizawa A, Saruta M, Yano Y, Ohno T, Uchimoto T, Fukuokaya W, Adachi T, Yamazaki S, Tokushige S, Nishimura K, Tsujino T, Nakamori K, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Hirasawa Y, Hashimoto T, Komura K, Inamoto T, Miki J, Kimura T, Ohno Y, Azuma H, Shiroki R. Nukaya T, et al. Among authors: azuma h. Clin Genitourin Cancer. 2024 Feb;22(1):76-83. doi: 10.1016/j.clgc.2023.09.007. Epub 2023 Oct 1. Clin Genitourin Cancer. 2024. PMID: 37880020
955 results